Fulvestrant is at least as effective with respect to survival as the selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer. It may be particularly suitable for patients likely to be noncompliant with oral medications.
Go to Previous Page
Go to Next Page